A combination vinorelbine-estramustine in patients with hormone refractory prostate cancer

被引：0
|
作者：
Butera, A. [1 ]
Tornabene, P. [1 ]
机构：
[1] UO Oncol Med AOS Giovanni Dio Agrigento, Vicenza, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：82 / 82
页数：1
相关论文
共 50 条
  • [31] PHASE II STUDY OF VINORELBINE AND ESTRAMUSTINE IN COMBINATION WITH CONFORMATIONAL RADIOTHERAPY FOR PATIENTS WITH HIGH-RISK PROSTATE CANCER
    Carles, Joan
    Nogue, Miguel
    Sole, Josep M.
    Foro, Palmira
    Domenech, Montserrat
    Suarez, Marta
    Gallardo, Enrique
    Garcia, Dario
    Ferrer, Ferran
    Gelabert-Mas, Antoni
    Gayo, Javier
    Fabregat, Xavier
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (04): : 1085 - 1091
  • [32] A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Lin, Amy M.
    Rini, Brian I.
    Derynck, Mika K.
    Weinberg, Vivian
    Park, Margaret
    Ryan, Charles J.
    Rosenberg, Jonathan E.
    Bubley, Glenn
    Small, Eric J.
    CLINICAL GENITOURINARY CANCER, 2007, 5 (05) : 323 - 328
  • [33] Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients
    Nakagami, Yoshihiro
    Ohori, Makoto
    Sakamoto, Noboru
    Koga, Shoji
    Hamada, Riu
    Hatano, Tadashi
    Tachibana, Masaaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (07) : 629 - 634
  • [34] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Goodin, S
    Rao, KV
    Kane, M
    Dave, N
    Capanna, T
    Doyle-Lindrud, S
    Engle, E
    Jin, LX
    Todd, M
    DiPaola, RS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) : 199 - 204
  • [35] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Susan Goodin
    Kamakshi V. Rao
    Michael Kane
    Nisha Dave
    Terry Capanna
    Susan Doyle-Lindrud
    Elizabeth Engle
    Lixian Jin
    Mary Todd
    Robert S. DiPaola
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 199 - 204
  • [36] Augmented cytotoxicity of estramustine and etoposide combination in hormone refractory prostate cancer cell lines and association with TGF modulation
    Türkeri, LN
    Ayaz, O
    Özyürek, M
    Akdas, A
    PROSTATE CANCER AND PROSTATIC DISEASES, 1999, 2 (Suppl 3) : S33 - S33
  • [37] Augmented cytotoxicity of estramustine and etoposide combination in hormone refractory prostate cancer cell lines and association with TGF modulation
    LN Türkeri
    O Ayaz
    M Özyürek
    A Akdas
    Prostate Cancer and Prostatic Diseases, 1999, 2 : S33 - S33
  • [38] COMPARISON OF ESTRAMUSTINE PHOSPHATE AND VINCRISTINE ALONE OR IN COMBINATION FOR PATIENTS WITH ADVANCED, HORMONE REFRACTORY, PREVIOUSLY IRRADIATED CARCINOMA OF THE PROSTATE
    SOLOWAY, MS
    DEKERNION, JB
    GIBBONS, RP
    JOHNSON, DE
    LOENING, SA
    PONTES, JE
    PROUT, GR
    SCHMIDT, JD
    SCOTT, WW
    CHU, TM
    GAETA, JF
    SLACK, NH
    MURPHY, GP
    JOURNAL OF UROLOGY, 1981, 125 (05): : 664 - 667
  • [39] Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer
    Noguchi, M
    Itoh, K
    Suekane, S
    Morinaga, A
    Sukehiro, A
    Suetsugu, N
    Katagiri, K
    Yamada, A
    Noda, S
    PROSTATE, 2004, 60 (01): : 32 - 45
  • [40] Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer
    Borrega, P
    Velasco, A
    Bolaños, M
    Pérez, MD
    Mel, JR
    Reina, JJ
    Rodríguez-Jaraiz, MA
    Chaves, M
    González-Barón, M
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (01) : 32 - 35
12345